Skip to content

A Clinical Trial to Evaluate the Clinical Therapeutic Value of 4-hour Hemoperfusion and the Influencing Factors of Its Safety in Maintenance Hemodialysis (MHD) Patients

A Clinical Trial to Evaluate the Clinical Therapeutic Value of 4-hour Hemoperfusion and the Influencing Factors of Its Safety in Maintenance Hemodialysis (MHD) Patients

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600120124
Enrollment
Unknown
Registered
2026-03-10
Start date
2026-03-18
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemoperfusion After Renal Injury

Interventions

2-hour Hemoperfusion Group:Prolonging the Duration of Hemoperfusion Therapy and Adjusting the Treatment Flow Rate of Hemoperfusion Combined with Hemodialysis
4-hour Hemoperfusion Group:Prolonging the Duration of Hemoperfusion Therapy and Adjusting the Treatment Flow Rate of Hemoperfusion Combined with Hemodialysis

Sponsors

Lianyungang First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged >= 18 years, regardless of gender; 2.Undergoing maintenance hemodialysis for more than 3 months; 3.Receiving regular hemodialysis treatment, 3 times per week and 4 hours per session; 4.No restrictions on vascular access; 5.Voluntarily participating in the trial and signing a written informed consent form.

Exclusion criteria

Exclusion criteria: 1.Subjects with a known history of allergy, contraindications, or intolerance to the materials of dialyzers or hemoperfusion cartridges; 2.Subjects with a platelet count < 60×10^9/L; 3.Subjects with a blood flow rate < 200 ml/min; 4.Subjects with other coagulation disorders, severe bleeding tendency, or active bleeding; 5.Subjects with hypotension or severe cardiopulmonary insufficiency; 6.Subjects currently or recently (within 30 days) participating in other drug research projects; 7.Subjects complicated with acute and critical illnesses such as acute infections, severe heart, lung, liver, or nervous system diseases, as well as malignant tumors.

Design outcomes

Primary

MeasureTime frame
Toxin Clearance Rate and Clinical Safety Before and After Perfusion;Solute clearance rate (ß2-MG, leptin, light chain protein, end-stage glycosylation products, blood phosphorus);

Secondary

MeasureTime frame
Optimization Effect of Clinical Nursing Care During Hemodialysis Combined With Hemoperfusion in This Study;Renal function (KT/V);Nursing workload;The amount of normal saline returned to the blood;

Countries

China

Contacts

Public ContactZhang Liyuan

Lianyungang First People's Hospital

2848610945@qq.com+86 18961322515

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026